Japan Panel Recommends Easing Rules To Allow Access To New Drugs
This article was originally published in PharmAsia News
Japan's Council for Regulatory Reform has recommended the government soften some of its regulations to ease patient access to get treatment with drugs not yet approved for their conditions.
You may also be interested in...
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.